Multiple Myeloma

Multiple Myeloma

A collection of features and news articles published in ASH Clinical News related to multiple myeloma.

On location

AMG 420 Continues to Show Efficacy in Relapsed/Refractory Myeloma

In updated results from the first-in-human study of the bispecific T-cell engager (BITE) AMG 420, the agent continued to demonstrate clinical activity in patients...
WIB_icon

Equal Access to Treatment Erases Difference in Outcomes Between White and African American Patients...

If African American patients with multiple myeloma (MM) are given equal access to treatments, they have outcomes that are as good as or better...

Daratumumab Combination Extends Progression-Free Survival for Transplant-Ineligible Myeloma

In patients with newly diagnosed multiple myeloma (MM) who were ineligible for autologous hematopoietic cell transplantation (AHCT), adding daratumumab to a regimen of lenalidomide...

FDA Grants Selinexor Accelerated Approval Despite Concerns With Trial Data

The U.S. Food and Drug Administration (FDA) granted accelerated approval to for selinexor, an oral selective inhibitor of nuclear export (SINE), for patients with...

FDA Lifts Partial Clinical Hold on Venetoclax Trial in Myeloma

Researchers can move forward with the phase III CANOVA trial, now that the U.S. Food and Drug Administration (FDA) has lifted a partial clinical...

FDA Approves Daratumumab for Patients with Transplant-Ineligible Myeloma

On June 27, 2019, the U.S. Food and Drug Administration (FDA) approved daratumumab, in combination with lenalidomide and dexamethasone, for patients with newly diagnosed...

Paul Richardson: Isatuximab Improves PFS in Relapsed/Refractory Myeloma

Paul Richardson, MD, shares results seen with isatuximab in heavily refractory myeloma, and discusses how this new agent compares with approved monoclonal antibodies.
On location

New Subcutaneous Daratumumab Formulation Overcomes Infusion Barrier for Patients

Daratumumab-based regimens have shown efficacy across all lines of therapy in multiple myeloma (MM), but the agent requires a long intravenous infusion time, lasting...
On location

Iberdomide: A New Immunomodulatory Drug for Heavily Refractory Myeloma

One-third of patients with relapsed/refractory multiple myeloma (MM) responded to treatment with the investigational agent iberdomide, according to early results from a first-in-human trial. Sagar...
On location

Isatuximab Combo Improves Progression-Free Survival in Pretreated Myeloma

In an update from the phase III ICARIA-MM trial, researchers reported that the combination of the anti-CD38 monoclonal antibody isatuximab with pomalidomide and dexamethasone...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.